5-nitro-N-(pyridin-3-ylmethyl)furan-2-carboxamide | 215778-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 5-nitro-N-(pyridin-3-ylmethyl)furan-2-carboxamide
• CAS: 215778-97-5
• 化学式: C11H9N3O4
• mdl: MFCD00218071
• 分子量: 247.21
• InChiKey: OBZHOVWNZIVCCZ-UHFFFAOYSA-N

物化性质

• 溶解度：
  在DMSO中的溶解度为20mg/mL，澄清

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] ECHINOMYCIN FORMULATION, METHOD OF MAKING AND METHOD OF USE THEREOF<br/>[FR] FORMULATION D'ÉCHINOMYCINE, PROCÉDÉ DE FABRICATION ET MÉTHODE D'UTILISATION DE CETTE DERNIÈRE
  申请人：CHILDREN'S RES INST CHILDREN'S NAT MEDICAL CENTER

  公开号：WO2017083403A1

  公开（公告）日：2017-05-18

  A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1α and/or HIF-2α includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

  一种脂质体药物制剂，用于治疗患有HIF-1α和/或HIF-2α过度表达的患者的疾病，包括在药学上可接受的载体中的多种脂质体。脂质体包含依奇诺霉素，并由聚乙二醇化磷脂、中性磷酸甘油酰胺和甾醇制成。聚乙二醇化脂质体可用于治疗增生性疾病、白血病、癌症、自身免疫性疾病和移植物抗宿主病。
• Method for determining the risk profile of neoplastic tissue
  申请人：NOVAZOI THERANOSTICS

  公开号：US10242153B2

  公开（公告）日：2019-03-26

  A method of computing the risk profile of a neoplastic tissue in a patient is disclosed. The method includes the steps of (a) processing a sample of tumor tissue or cancer cells from the patient in a form suitable for visualization and demarcation of cell nuclei, individually distinguishable centrosomes (iCTRs) and megacentrosomes (mCTRs) in a region of interest (ROI) defined by a plurality of cell nuclei; (b) determining the numbers of iCTRs and mCTRs associated with each cell nucleus in the ROI; (c) determining the volume of each iCTR and mCTR in the ROI; and (d) calculating one or more centrosome amplification scores (CASs) values for the sample based on steps (b) and (c), wherein the one or more CASs indicate the severity of centrosome amplification, the frequency of centrosome amplification, or both, and wherein the one or more scores provide a measure of a level of risk and/or a prognosis associated with the neoplastic tissue.

  本发明公开了一种计算患者肿瘤组织风险概况的方法。该方法包括以下步骤：(a) 在由多个细胞核定义的感兴趣区（ROI）中，以适合可视化和划分细胞核、可单独区分的中心体（iCTRs）和巨中心体（mCTRs）的形式，处理来自患者的肿瘤组织或癌细胞样本；(b) 确定与 ROI 中每个细胞核相关的 iCTRs 和 mCTRs 的数量；(c) 确定 ROI 中每个 iCTR 和 mCTR 的体积；以及 (d) 根据步骤(b)和(c)计算样本的一个或多个中心体扩增评分（CAS）值，其中一个或多个 CAS 表示中心体扩增的严重程度、中心体扩增的频率或两者兼而有之，其中一个或多个评分提供了与肿瘤组织相关的风险和/或预后水平的度量。
• Checkpoint regulator antagonists
  申请人：GENSUN BIOPHARMA INC.

  公开号：US10537637B2

  公开（公告）日：2020-01-21

  Checkpoint regulator antagonists that bind specifically to TIGIT, PD-1 and/or PD-L1 are disclosed. Also disclosed are methods of making and using the checkpoint regulator inhibitors, including monospecific, bispecific and trispecific checkpoint regulator antagonists thereof.

  本研究公开了与 TIGIT、PD-1 和/或 PD-L1 特异性结合的检查点调节剂拮抗剂。还公开了制造和使用检查点调节剂抑制剂的方法，包括单特异性、双特异性和三特异性检查点调节剂拮抗剂。
• Antitumor immune checkpoint regulator antagonists
  申请人：GENSUN BIOPHARMA, INC.

  公开号：US10597453B2

  公开（公告）日：2020-03-24

  Antitumor antagonists that bind specifically to immune checkpoint regulator are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.

  本研究公开了与免疫检查点调节剂特异性结合的抗肿瘤拮抗剂。还公开了一种用抗肿瘤拮抗剂治疗增殖性疾病的方法。
• Trispecific antagonists
  申请人：GENSUN BIOPHARMA, INC.

  公开号：US10647773B2

  公开（公告）日：2020-05-12

  Antitumor antagonists that bind specifically to immune checkpoint regulator and/or components of the angiogenesis pathways and/or components of the TGF pathway are disclosed. Also disclosed is a method of treating proliferative disorders with the antitumor antagonists.

  本发明公开了与免疫检查点调节剂和/或血管生成途径成分和/或 TGF 途径成分特异性结合的抗肿瘤拮抗剂。还公开了一种用抗肿瘤拮抗剂治疗增殖性疾病的方法。